10-Q: Bio Essence Corp. Reports Q3 2024 Results, Navigates Discontinued Operations and Going Concern Challenges

Bio Essence Corp.'s Q3 2024 results show a net loss, the impact of discontinued operations, and ongoing concerns about the company's ability to continue as a going concern.

Summary

• Bio Essence Corp. reported a net loss of $1,281,233 for the nine months ended September 30, 2024, and a net loss of $1,199,493 for the three months ended September 30, 2024.
• The company's accumulated deficit reached $10,421,707 as of September 30, 2024, raising substantial doubt about its ability to continue as a going concern.
• Revenues from continuing operations were $176,385 for the nine months and $134,690 for the three months ended September 30, 2024.
• The company completed the sale of its subsidiaries, BEP and BEH, for $300,000 and $400,000 respectively, resulting in a gain on disposal of discontinued operations of $377,752.
• Operating expenses increased significantly, primarily due to increased office rent and consulting fees.
• The company is exploring options to raise additional funds, including private or public offerings and loans.
• The company's current liabilities exceed current assets, resulting in a working capital deficit of $2,351,386 as of September 30, 2024.

Sentiment

Score: 2

Explanation: The document reveals significant financial distress, a going concern issue, and ineffective internal controls, leading to a very negative sentiment.

Positives

• The company successfully sold its subsidiaries, BEP and BEH, generating a gain of $377,752.
• Revenues from continuing operations were $176,385 for the nine months ended September 30, 2024, compared to $0 in the same period last year.
• The company is actively seeking new business opportunities and exploring potential acquisitions.
• The company is exploring options to raise additional funds through private or public offerings, or loans.

Negatives

• The company incurred a significant net loss of $1,281,233 for the nine months ended September 30, 2024.
• The accumulated deficit of $10,421,707 raises substantial doubt about the company's ability to continue as a going concern.
• Operating expenses increased significantly, particularly general and administrative expenses.
• The company recorded a $1,050,940 impairment loss on right-of-use assets.
• The company has a working capital deficit of $2,351,386.
• The company's disclosure controls and procedures are not effective.

Risks

• The company's ability to continue as a going concern is uncertain due to significant losses and accumulated deficit.
• The company may not be able to raise additional funds on reasonable terms or at all.
• The company's current liabilities exceed its current assets, posing a liquidity risk.
• The company's internal controls over financial reporting are not effective.
• The company is dependent on loans from a major shareholder, which are payable on demand.

Future Outlook

The company intends to increase its income by strengthening its sales force, providing attractive sales incentive programs, and increasing marketing and promotion activities. Management also intends to raise additional funds by way of a private or public offering, or by obtaining loans from banks or others. The company is also actively seeking other business opportunities including expanding OEM business and looking for potential acquisition targets.

Management Comments

• Management believes in the viability of its strategy to generate sufficient revenue and in its ability to raise additional funds on reasonable terms and conditions, but there can be no assurances to that effect.
• Management concluded that, as of September 30, 2024, the company's disclosure controls and procedures are not effective.
• Management concluded that, as of September 30, 2024, the company's internal control over financial reporting were not effective at the reasonable assurance level.

Industry Context

The health supplement industry is competitive, and Bio Essence Corp. is facing challenges in generating revenue and managing expenses. The company's decision to sell its subsidiaries and focus on OEM services reflects a strategic shift in response to these challenges. The company's financial difficulties are not uncommon for smaller companies in this sector, which often face challenges in scaling operations and achieving profitability.

Comparison to Industry Standards

• The company's negative profitability and working capital deficit are significantly below industry standards for established health supplement companies.
• Comparable companies such as Herbalife and Nu Skin typically report positive net income and strong cash flow from operations.
• The impairment of the right-of-use asset is unusual and indicates significant issues with lease management, which is not typical for well-managed companies.
• The reliance on loans from a major shareholder is not a sustainable long-term financing strategy and is not common among publicly traded companies.
• The lack of effective internal controls is a serious concern and is not in line with the standards expected of public companies.

Related Party Transactions

• The Company held loans from one major shareholder (also the Company's senior officer) for $1,028,746 and $1,180,046, respectively, at September 30, 2024 and December 31, 2023.
• The Company held a loan from another major shareholder for $608,631 for settling the litigation.
• On May 31, 2023, the Board of Directors of Bio Essence Corp. approved a debt-to-equity conversion with Ms. Yan, the company's CEO and major shareholder.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and potential dilution from future capital raises.
• Employees may be concerned about job security due to the company's going concern issues.
• Customers may be affected by potential disruptions in the company's operations.
• Suppliers and creditors face increased risk of non-payment due to the company's financial difficulties.

Next Steps

• The company will continue to explore options to raise additional funds.
• The company will work on implementing controls and procedures to remedy the ineffectiveness of disclosure controls.
• The company will continue to develop internal controls over financial reporting.
• The company will continue to seek new business opportunities and potential acquisition targets.

Key Dates

Keywords

financial results, quarterly report, net loss, discontinued operations, going concern, lease impairment, working capital, revenue, operating expenses, debt, capital raise